Abstract
Background: The influence of inflammatory bowel disease (IBD) location on vedolizumab efficacy is unclear. Our goal was to determine whether IBD location has an influence on the rate of steroidfree clinical remission (SFCR) at week 24 under vedolizumab. Method(s): We included in a retrospective multicentre study all consecutive patients with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) receiving vedolizumab from 2014 to 2017. SFCR was assessed at week 24 and defined by a Harvey-Bradshaw Index (HBI)
Cite
CITATION STYLE
Pestour, S., Nancey, S., Charlois, A. L., Bonaz, B., Flourie, B., Boschetti, G., & Mathieu, N. (2018). DOP050 Influence of disease location on vedolizumab efficacy in inflammatory bowel disease: a real-life multicentre experience. Journal of Crohn’s and Colitis, 12(supplement_1), S065–S066. https://doi.org/10.1093/ecco-jcc/jjx180.087
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
